Aerie Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AERI Nasdaq 2834 http://www.aeriepharma.com 22.41 Stock Up +0.10

Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014 - Mar 6th, 2014 6:41 am
Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014 - Mar 6th, 2014 5:30 am
AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Mar 5th, 2014 10:13 am
Aerie Pharmaceuticals to Present at the 26th Annual ROTH Conference - Mar 5th, 2014 6:28 am
Aerie Pharmaceuticals to Present at the 26th Annual ROTH Conference - Mar 5th, 2014 5:30 am
AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Feb 27th, 2014 11:06 am
Aerie Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference - Feb 27th, 2014 6:26 am
Aerie Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference - Feb 27th, 2014 5:30 am
AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Feb 26th, 2014 4:39 am
Aerie Pharmaceuticals Announces Study Results Supporting Additional Mechanism of Action for Lead Glaucoma Drug Candidate AR-13324 - Feb 25th, 2014 6:30 am
AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Feb 25th, 2014 4:34 am
Aerie Pharmaceuticals Announces Study Results Supporting Additional Mechanism of Action for Lead Glaucoma Drug Candidate AR-13324 - Feb 25th, 2014 4:30 am
Aerie Pharmaceuticals Names Marvin J. Garrett as Vice President, Regulatory Affairs and Quality Assurance - Feb 24th, 2014 3:20 pm
Aerie Pharmaceuticals Names Marvin J. Garrett as Vice President, Regulatory Affairs and Quality Assurance - Feb 24th, 2014 2:30 pm
AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Feb 19th, 2014 3:19 pm
Aerie Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference - Feb 19th, 2014 6:10 am
Aerie Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference - Feb 19th, 2014 5:30 am
Aerie Pharmaceuticals initiats Phase 2b study of PG324 - Jan 30th, 2014 2:45 pm
AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Jan 30th, 2014 2:32 pm
Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension - Jan 30th, 2014 2:30 pm